This study suggests that baseline serum HE4, but not tissue HE4 expression, is a predictive biomarker for response to LNG-IUS treatment in stage Ia EEC and AH, and higher levels of serum HE4 independently predict resistance to treatment. Here, WFDC2 is linked to exstrophy-epispadias complex.